Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of ONO-4538HSC in advanced or metastatic solid tumors
jRCT2011230059Phase 1Active, not recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nivolumab in Nonhematologic neoplasms and solid tumor, sponsored by Ono Pharmaceutical. Primary endpoints: Tolerability of ONO-4538HSC and Safety of ONO-4538HSC. Started May 2024; status: active, not recruiting.
02
Drugs
03
Conditions
Nonhematologic neoplasmssolid tumor
Beyond the preview
Go deeper on jRCT2011230059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011230059.